The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Insulin Dysfunction Induces In Vivo Tau Hyperphosphorylation through Distinct Mechanisms
Open accessAbstract
Hyperphosphorylated tau is the major component of paired helical filaments in neurofibrillary tangles found in Alzheimer's disease (AD) brains, and tau hyperphosphorylation is thought to be a critical event in the pathogenesis of the disease. The large majority of AD cases is late onset and sporadic in origin, with aging as the most important risk factor. Insulin resistance, impaired glucose tolerance, and diabetes mellitus (DM) are other common syndromes in the elderly also strongly age dependent, and there is evidence supporting a link between insulin dysfunction and AD. To investigate the possibility that insulin dysfunction might promote tau pathology, we induced insulin deficiency and caused DM in mice with streptozotocin (STZ). A mild hyperphosphorylation of tau could be detected 10, 20, and 30 d after STZ injection, and a massive hyperphosphorylation of tau was observed after 40 d. The robust hyperphosphorylation of tau was localized in the axons and neuropil, and prevented tau binding to microtubules. Neither mild nor massive tau phosphorylation induced tau aggregation. Body temperature of the STZ-treated mice did not differ from control animals during 30 d, but dropped significantly thereafter. No change in β-amyloid (Aβ) precursor protein (APP), APP C-terminal fragments, or Aβ levels were observed in STZ-treated mice; however, cellular protein phosphatase 2A activity was significantly decreased. Together, these data indicate that insulin dysfunction induced abnormal tau hyperphosphorylation through two distinct mechanisms: one was consequent to hypothermia; the other was temperature-independent, inherent to insulin depletion, and probably caused by inhibition of phosphatase activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Risk of dementia in diabetes mellitus: a systematic review
Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C., & Scheltens, P. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70284-2 · Cited by 2,187
Pathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342
Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258 · cited 2×
“higher AD incidence rates in type 2 DM patients (Leibson et al., 1997; Ott et al., 1999; Peila et al., 2002; Arvanitakis et al., 2004; Luchsinger et al., 2005).”
BackgroundType 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies
Peila, R., Rodriguez, B. L., & Launer, L. J. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1256 · Cited by 1,207 · cited 1×
“Many longitudinal population-based studies have detected higher AD incidence rates in type 2 DM patients (Leibson et al., 1997; Ott et al., 1999; Peila et al., 2002; Arvanitakis et al., 2004; Luchsinger et al., 2005).”
BackgroundRole of tau protein in both physiological and pathological conditions
AVILA, J., LUCAS, J. J., PÉREZ, M., & HERNÁNDEZ, F. (2004) · Physiological Reviews · doi:10.1152/physrev.00024.2003 · Cited by 1,005 · cited 1×
“Impact of diabetes on tau binding to microtubules Tau is a microtubule-associated protein whose function is to bind an stabilize MTs, and tau binding to MTs is regulated by phosphorylation (Avila et al., 2004).”
BackgroundBancher, C., Brunner, C., Lassmann, H., Budka, H., Jellinger, K., Wiche, G., Seitelberger, F., Grundke-Iqbal, I., Iqbal, K., & Wisniewski, H. M. (1989) · Brain Research · doi:10.1016/0006-8993(89)91396-6 · Cited by 818
O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer's disease
Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G. W., & Gong, C.-X. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400348101 · Cited by 775 · cited 2×
“For example, diabetes can affect protein glycosylation (Williams et al., 1982), and glycosylation has been shown to modulate tau phosphorylation (Liu et al., 2004).”
BackgroundRole of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease.
Alonso, A. C., Zaidi, T., Grundke-Iqbal, I., & Iqbal, K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5562 · Cited by 738
Rivera, E. J., Goldin, A., Fulmer, N., Tavares, R., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8304 · Cited by 723 · cited 2×
“, 1999), decreased brain insulin and insulin-like growth factor I expression and function (Rivera et al., 2005), and reduced glucose metabolism (Mosconi, 2005).”
BackgroundNoble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500466102 · Cited by 709 · cited 2×
“Tau solubility was analyzed by a modification of the protocol of Greenberg and Davies (1990) (Noble et al., 2005).”
MethodSelf-citationRisk of Dementia among Persons with Diabetes Mellitus: A Population-based Cohort Study
Leibson, C. L., Rocca, W. A., Hanson, V. A., Cha, R., Kokmen, E., O'Brien, P. C., & Palumbo, P. J. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009106 · Cited by 700
Yankner, B. A., Lu, T., & Loerch, P. (2008) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.2.010506.092044 · Cited by 677
Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205
Goedert, M., Jakes, R., & Vanmechelen, E. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11484-e · Cited by 608
Craft, S., Peskind, E., Schwartz, M. W., Schellenberg, G. D., Raskind, M., & Porte, D. (1998) · Neurology · doi:10.1212/wnl.50.1.164 · Cited by 560
Phosphoprotein Phosphatase Activities in Alzheimer Disease Brain
Gong, C., Singh, T. J., Grundke‐Iqbal, I., & Iqbal, K. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03603.x · Cited by 527 · cited 1×
“In AD, decreased PP2A expression (Vogelsberg-Ragaglia et al., 2001) along with upregulation of its inhibitors (Tanimukai et al., 2005), results in overall inhibition of its activity (Gong et al., 1993, 1995), which might be an important factor in the evolution of the pathology (Tian and Wang, 2002).”
BackgroundBolli, G., Feo, P. D., Compagnucci, P., Cartechini, M. G., Angeletti, G., Santeusanio, F., Brunetti, P., & Gerich, J. E. (1983) · Diabetes · doi:10.2337/diab.32.2.134 · Cited by 433
Goedert, M., Jakes, R., Crowther, R. A., Cohen, P., Vanmechelen, E., Vandermeeren, M., & Cras, P. (1994) · Biochemical Journal · doi:10.1042/bj3010871 · Cited by 375
PP2A mRNA Expression Is Quantitatively Decreased in Alzheimer's Disease Hippocampus
Vogelsberg-Ragaglia, V., Schuck, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7630 · Cited by 281 · cited 1×
“In AD, decreased PP2A expression (Vogelsberg-Ragaglia et al., 2001) along with upregulation of its inhibitors (Tanimukai et al., 2005), results in overall inhibition of its activity (Gong et al., 1993, 1995), which might be an important factor in the evolution of the pathology (Tian and Wang, 2002).”
BackgroundItoh, N., Arai, H., Urakami, K., Ishiguro, K., Ohno, H., Hampel, H., Buerger, K., Wiltfang, J., Otto, M., Kretzschmar, H., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1054 · Cited by 256 · cited 1×
“Furthermore, detection of PS199 in the CSF can be used in the antemortem diagnostic of AD (Itoh et al., 2001).”
Maas, T., Eidenmüller, J., & Brandt, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000389200 · Cited by 226 · cited 2×
“The microtubule (MT)-binding assay was performed as described previously (Maas et al., 2000), with a few modifications.”
MethodUp-regulation of inhibitors of protein phosphatase-2A in Alzheimer’s disease
Tanimukai, H., Grundke-Iqbal, I., & Iqbal, K. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62486-8 · Cited by 220
Maurage, C.-A., Sergeant, N., Ruchoux, M.-M., Hauw, J.-J., & Delacourte, A. (2003) · Acta Neuropathologica · doi:10.1007/s00401-002-0608-7 · Cited by 51 · cited 1×
“Early phosphorylation at PS199 is particularly interesting because this epitope enables the visualization of early stages of tau pathology, even when aggregates of tau are not detectable by biochemical approaches (Maurage et al., 2003).”
Background
Cited by
Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications
Biessels, G. J., & Despa, F. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0048-7 · Cited by 1,454
Craft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
Tau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Morris, M., Maeda, S., Vossel, K., & Mucke, L. (2011) · Neuron · doi:10.1016/j.neuron.2011.04.009 · Cited by 899
“Tau also becomes hyperphosphorylated in mouse brain in response to hypothermia and experimental insulin-dependent diabetes (Planel et al., 2007).”
BackgroundBiochemistry and Cell Biology of Tau Protein in Neurofibrillary Degeneration
Mandelkow, E.-M., & Mandelkow, E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006247 · Cited by 847
Metadata
- Authors
- Planel, E., Tatebayashi, Y., Miyasaka, T., Liu, L., Wang, L., Herman, M., Yu, W. H., Luchsinger, J. A., Wadzinski, B., Duff, K. E., & Takashima, A.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2007-12-12
- Volume
- 27
- Issue
- 50
- Pages
- 13635-13648
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2066232800
- Cited by
- 237
- References
- 23
- FWCI
- 6.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.